Reduction of pain in the treatment of vascular lesions with a pulsed dye laser and pneumatic skin flattening.
The treatment of vascular lesions, including port wine stains (PWSs), with a pulsed dye laser is very painful and often requires general anaesthesia. This is particularly problematic with children. Pneumatic skin flattening (PSF) is a new technology that naturally reduces pain in laser-based aesthetic treatments. The objective of this study was to test pain reduction, as well as lesional clearance, by combining pneumatic skin flattening (PSF) technology with a pulsed dye laser in the treatment of vascular lesions. Twenty-one patients (three of them children) were treated for vascular lesions, mostly PWSs (13 patients). The patients were treated with a 595 nm pulsed dye laser operated at energies of 5.75-13.25 (median 9.25) J/cm(2). Acute pain was evaluated in all 21 patients. Topical anaesthetic (EMLA cream) was applied before treatment in six cases. Identical energies were applied to both sites. The pain during PSF treatment was compared to pain during regular treatment without PSF. Blanching response to treatment was evaluated in 18 patients after 6-12 weeks. Significant pain reduction was observed in 21/21 patients (100%). The average reduction in pain score was from 10 without PSF (painful) to 2.6 with PSF (comfortable). Follow-up examination of 18 patients after 6-12 weeks showed identical blanching of tissue in both the PSF-treated areas and those not treated with PSF in all patients. It was concluded that the PSF technology significantly reduced pain in the treatment of vascular lesions with a pulsed dye laser without affecting efficacy.
Lanigan
Sean
S
Birmingham Skin Centre, City Hospital, Birmingham, UK. sean.lanigan@swbh.nhs.uk
D000328:Adult; D002648:Child; D006801:Humans; D048228:Intermittent Pneumatic Compression Devices; D007627:Keloid / Q000532:radiotherapy; D007642:Keratosis / Q000532:radiotherapy; D054025:Lasers, Dye / Q000009:adverse effects; D028022:Low-Level Light Therapy / Q000009:adverse effects / Q000379:methods*; D010146:Pain / Q000209:etiology / Q000517:prevention & control*; D019339:Port-Wine Stain / Q000473:pathology / Q000532:radiotherapy*; D012393:Rosacea / Q000532:radiotherapy; D012867:Skin / Q000098:blood supply / Q000528:radiation effects; D012868:Skin Abnormalities / Q000473:pathology / Q000532:radiotherapy; D013997:Time Factors